In lung cancer, TRIM46 activates AKT/HK2 signaling by modifying PHLPP2 ubiquitination to promote glycolysis and chemoresistance, which reflects the importance of TRIM46/PHLPP2/AKT signaling in lung cancer and provides a new strategy for lung cancer treatment (Tantai et al., 2022) (Table 4). The gene discussed is AKT1; the disease is lung cancer.